Products
Clinical Trials
Find the latest clinical trials by condition, location & phase
Drugs
Browse and search for drug monographs and related information
Drug Products
Approved pharmaceutical products by global regulatory authorities
US
FDA Products
EU
EMA Products
SG
HSA Products
CN
NMPA Products
HK
PPB Products
AU
TGA Products
Companies
Explore a comprehensive list of organizations, including their profiles and details
News
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Research
Pricing
FAQ
Pharmaceutical Companies
Pharma Details
JANSSEN RESEARCH & DEVELOPMENT, LLC
🇺🇸
United States
Country
🇺🇸
United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Phase 3
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Daratumumab IV
Drug: Lenalidomide
Drug: Daratumumab SC
Drug: Dexamethasone
Subscribe
First Posted Date
2014-09-30
Last Posted Date
2025-06-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
737
Registration Number
NCT02252172
Subscribe
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
Phase 2
Completed
Conditions
Obesity
Interventions
Drug: Phentermine
Drug: Canagliflozin
Drug: Matching Placebo to Phentermine
Drug: Matching Placebo to Canagliflozin
Subscribe
First Posted Date
2014-09-17
Last Posted Date
2016-10-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
335
Registration Number
NCT02243202
Subscribe
Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma
Phase 1
Terminated
Conditions
Asthma
Healthy
Interventions
Drug: JNJ-43260295
Drug: Placebo
Drug: Nasal Allergen Challenge
Subscribe
First Posted Date
2014-09-17
Last Posted Date
2016-03-23
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
17
Registration Number
NCT02243189
Subscribe
Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-42756493 Tablet
Drug: JNJ-42756493 Capsule
Drug: JNJ-61818549
Subscribe
First Posted Date
2014-09-04
Last Posted Date
2014-12-03
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
12
Registration Number
NCT02231489
Subscribe
Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)
Completed
Conditions
Prostatic Neoplasms
Interventions
Other: No Intervention
Subscribe
First Posted Date
2014-09-03
Last Posted Date
2014-09-25
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
382
Registration Number
NCT02230059
Subscribe
Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Abiraterone acetate (Treatment A)
Drug: Abiraterone acetate (Treatment B)
Subscribe
First Posted Date
2014-09-03
Last Posted Date
2016-01-20
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
102
Registration Number
NCT02230046
Subscribe
Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Esketamine
Drug: Mirtazapine
Drug: Placebo (Matched to Esketamine)
Drug: Placebo (Matched to Mirtazapine)
Subscribe
First Posted Date
2014-08-28
Last Posted Date
2014-12-30
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
26
Registration Number
NCT02228239
Subscribe
Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults
Early Phase 1
Completed
Conditions
Healthy
Subscribe
First Posted Date
2014-08-20
Last Posted Date
2014-09-15
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
16
Registration Number
NCT02221726
Subscribe
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
Conditions
Bioequivalence
Interventions
Drug: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
Drug: Canagliflozin
Drug: Metformin
Subscribe
First Posted Date
2014-08-20
Last Posted Date
2014-11-25
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
2
Registration Number
NCT02221180
Subscribe
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Drug: Canagliflozin
Drug: Metformin IR
Subscribe
First Posted Date
2014-08-19
Last Posted Date
2014-11-19
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
2
Registration Number
NCT02220218
Subscribe
Prev
1
61
62
63
64
65
89
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy